By: Benzinga
J.P. Morgan Reiterates Overweight Rating on Valeant Pharmaceuticals International on Obagi Acquisition
In a report published Wednesday, J.P. Morgan analyst Chris Schott reiterated an Overweight rating on Valeant Pharmaceuticals International (NYSE: VRX ). In the report, Schott noted, “This morning, Valeant announced the acquisition of Obagi Medical for $360 mm. While incrementally small relative to Valeant's overall $4.7 bn in sales and
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here